search

Active clinical trials for "Myeloproliferative Disorders"

Results 491-500 of 564

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant...

Breast CancerChronic Myeloproliferative Disorders9 more

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host disease. PURPOSE: This clinical trial is studying T cells to see how well they help in predicting acute graft-versus-host disease in patients undergoing donor stem cell transplant.

Terminated6 enrollment criteria

Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer...

Childhood Langerhans Cell HistiocytosisLeukemia4 more

RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood and placental blood transplantation in treating patients who have hematologic cancer or aplastic anemia.

Unknown status37 enrollment criteria

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Adult Langerhans Cell HistiocytosisChildhood Langerhans Cell Histiocytosis5 more

RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.

Terminated40 enrollment criteria

Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

Primary MyelofibrosisPrimary Pulmonary Hypertension2 more

To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.

Terminated5 enrollment criteria

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic...

LeukemiaMyelodysplastic Syndromes1 more

RATIONALE: Decitabine may help myelodysplasia cells develop into normal stem cells. It is not yet known if decitabine is more effective than standard supportive care in treating myelodysplastic syndrome. PURPOSE: Randomized phase III trial to compare the effectiveness of low-dose decitabine with that of standard supportive care in treating older patients who have myelodysplastic syndrome.

Unknown status59 enrollment criteria

Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia...

Myeloproliferative Neoplasms (MPN)Polycythemia Vera (PV)2 more

This study involves screening for portal vein thrombosis and portal hypertension in patients with Philadelphia negative myeloproliferative neoplasms (MPNs). These include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis. Portal vein thrombosis and portal hypertension are serious complications that are often seen in myeloproliferative patients. These complications are usually diagnosed when patients become symptomatic, and are often already at an advanced stage. They can further progress to cause non-reversible damage to the liver, also called cirrhosis of the liver. As a result of this, patients often accumulate fluid in the abdomen which is ascites; and can develop swelling of veins in the lining of the esophagus known as varices. If untreated, varices have the risk of rupturing resulting in life-threatening bleeding. When diagnosed at an advanced stage, the treatment is usually supportive therapy and there are no treatments available at present which can reverse these conditions. This study is looking at screening for these two conditions using Doppler ultrasound and upper gastrointestinal endoscopy.

Completed9 enrollment criteria

Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT

Acute Myeloid LeukemiaAcute Lymphoid Leukemia4 more

To evaluate if hyper-fractionated TBI or TMLI followed by Treg/Tcon adoptive immunotherapy improve cGvHD/disease free survival after allogeneic HSCT in patients affected by high-risk acute leukemias or other hematologic malignancy where HSCT is indicated.

Unknown status19 enrollment criteria

A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related diseases. The activation of the JAK/STAT pathway is related to abnormal proliferation, obstruction of apoptosis, and differentiation disorder of leukemia cells which is caused by genetic abnormalities and viral infection.

Unknown status8 enrollment criteria

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer...

Myeloproliferative DisordersLeukemia6 more

RATIONALE: Antiemetic drugs, such as aprepitant and ondansetron, may help lessen nausea and vomiting caused by opioids. It is not yet known whether aprepitant is more effective than ondansetron in treating nausea and vomiting caused by opioids in patients with cancer. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to ondansetron in treating nausea and vomiting caused by opioids in patients with cancer.

Withdrawn23 enrollment criteria

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients...

Accelerated Phase Chronic Myelogenous LeukemiaBCR-ABL1 Positive12 more

This randomized phase II trial studies how well multi-antigen cytomegalovirus (CMV)-modified vaccinia Ankara vaccine works in reducing CMV related complications in patients with blood cancer who are undergoing donor stem cell transplant. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells.

Withdrawn36 enrollment criteria
1...495051...57

Need Help? Contact our team!


We'll reach out to this number within 24 hrs